GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system, today announced an agreement with Companion Medical to integrate Eversense® CGM System real-time glucose data with the Companion Medical InPen™ smart system for insulin delivery. For people living with insulin-dependent diabetes, this news means that real-time glucose data will continuously be incorporated into their InPen insulin system allowing for more relevant insulin dosing information which will inform improved diabetes management decisions.
“There is a strong desire from people living with diabetes to have a complete picture of their real-time glucose values, rate of change and insulin information in one place so they can make better diabetes management decisions,” said Tim Goodnow, PhD, President and CEO of Senseonics. “By partnering with Companion Medical, multiple daily injection patients using the InPen System will be able to take full advantage of the convenience of insightful and comprehensive insulin data integrated with their Eversense CGM data, giving them a more complete picture and meaningful information at their fingertips.”
“CGM has revolutionized glucose monitoring and InPen has revolutionized MDI therapy. Together this is going to be a new world for those of us who manage our diabetes with MDI. Combining these technologies is a real game-changer,” said Companion’s Chief Executive Officer Sean Saint. “At Companion Medical our mission is to create affordable, easy-to-use solutions that allow people with insulin-dependent diabetes to focus more on their lives and less on their condition and the team at Senseonics is a great partner with a similar vision. We are excited about what our partnership with Senseonics will bring to those living with diabetes, their healthcare teams, payers and the smart pen category overall.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. Eversense users now have the freedom to make treatment decisions based on their Eversense readings. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
InPen was developed to empower people living with diabetes to live a less complicated life with diabetes by simplifying insulin dosing. The InPen system helps overcome the most common insulin dosing challenges including miscalculating doses, accidentally missed insulin doses, and low glucose due to insulin stacking.
The InPen system consists of a Bluetooth® enabled smart insulin pen that automatically tracks every dose and an integrated diabetes management app that helps patients make more informed decisions about when and how much rapid-acting insulin to take. The app includes a dose calculator to help calculate the rapid-acting doses, tracks insulin-on-board to help minimize risks of insulin stacking, offers dose reminders to minimize missed doses, provides an integrated automatic logbook, allows BG meter data integration and now will include real-time Eversense CGM data. Healthcare providers are easily able to access all their patients’ data via the shareable reports to inform therapy adjustments.
Patients who are interested in getting started on Eversense can sign up at www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).
Patients who are interested in a free-no obligation insurance check of InPen, visit www.companionmedical.com/get-inpen. Healthcare Professionals interested in learning more, contact 844-843-7903 or support@companionmedical.com.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a healthcare provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Companion Medical, Inc.
Companion Medical (www.companionmedical.com) was created in 2013 by people living with diabetes with the aim of making improved diabetes outcomes more attainable. InPen™, America’s first and only FDA cleared injection management system, is an affordable and easy-to-use solution that helps people living with diabetes take the right amount of insulin at the right time. InPen helps simplify insulin therapy by using the power of the smartphone to help users take control of their diabetes with the aim of improved outcomes for patients, providers, and payers.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about the completion of integration and development work on the Senseonics Eversense and Companion Medical InPen platforms, future features that will be available, and the potential benefits Eversense, InPen or the integration of platforms offers people with diabetes, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties in the development and regulatory approval processes, uncertainties inherent in the commercial launch and commercial expansion of the product, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2018, Senseonics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
